Compare LWAY & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWAY | ELDN |
|---|---|---|
| Founded | 1986 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.3M | 229.3M |
| IPO Year | 1995 | 2014 |
| Metric | LWAY | ELDN |
|---|---|---|
| Price | $18.30 | $2.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $35.00 | $8.50 |
| AVG Volume (30 Days) | 46.1K | ★ 1.3M |
| Earning Date | 03-17-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.33 | 30.67 |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $103,350,000.00 | N/A |
| Revenue This Year | $15.20 | N/A |
| Revenue Next Year | $16.67 | N/A |
| P/E Ratio | $20.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.31 | $1.35 |
| 52 Week High | $34.20 | $4.60 |
| Indicator | LWAY | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 33.21 | 55.10 |
| Support Level | $17.31 | $2.48 |
| Resistance Level | $22.80 | $3.15 |
| Average True Range (ATR) | 0.86 | 0.22 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 23.21 | 34.58 |
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.